Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Digene Corporation (NasdaqNM:DIGE)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Recent Events
Aug 16Conference call: Digene Corporation Q4/FYE Earnings
Aug 16Earnings Announcement
Location
1201 Clopper Road
Gaithersburg, MD 20878
Phone: (301) 944-7000
Fax: (301) 944-7017
Email: inforeq@digene.com
Employees (last reported count): 148
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 35%
·Institutional: 44% (68% of float)
(128 institutions)
·Net Inst. Buying: 267.0K shares (+3.47%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Digene Corporation develops, manufactures and markets proprietary DNA and RNA testing systems for the screening, monitoring and diagnosis of human diseases. The Company has developed and is commercializing its patented Hybrid Capture Gene Analysis System and tests in three areas: women's cancers and infectious diseases, blood viruses, and genomics and pharmaceutical research. The Company's lead product, the Hybrid Capture II HPV Test, is the only FDA-approved test for the detection of human papillomavirus (HPV), which is the cause of greater than 99% of cervical cancer cases. In addition, Digene has developed and launched tests internationally for the detection and viral load monitoring of major blood viruses, including cytomegalovirus and hepatitis B virus, and tests for the detection of two of the most common sexually transmitted infections, chlamydia and gonorrhea.
More from Market Guide: Expanded Business Description

Financial Summary
Digene Corporation develops, manufactures and market proprietary DNA and RNA testing systems for the screening, monitoring and diagnosis of human disease. For the fiscal year ended 6/30/01, total revenues increased 48% to $34.2 million. Net loss decreased 4% to $6.5 million. Revenues reflect higher sales of HPV tests and related equipment. Lower loss was partially offset by lower margins due to facility relocation and product mix, and increased personnel costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Evan Jones, 43
CEO and Chairman
$322K$1.5M
Charles Fleischman, 42
Pres, COO and Chief Financial Officer
328K4.1M
Robert Lilley, 55
Sr. VP, Global Sales and Marketing
347K559K
Attila Lorincz, Ph.D., 45
Sr. VP and CSO
252K2.1M
Joseph Slattery, 35
VP-Fin.
--  --  
Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:DIGEAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$10.625
Recent Price$29.51 
52-Week High
on 29-Dec-2000
$45.00 
Beta1.30 
Daily Volume (3-month avg)120.1K
Daily Volume (10-day avg)118.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-31.3%
52-Week Change
relative to S&P500
-7.8%
Share-Related Items
Market Capitalization$493.7M
Shares Outstanding16.7M
Float10.9M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$1.57 
Earnings (ttm)-$0.39 
Earnings (mrq)-$0.08 
Sales (ttm)$2.06 
Cash (mrq)$1.77 
Valuation Ratios
Price/Book (mrq)18.75 
Price/EarningsN/A 
Price/Sales (ttm)14.29 
Income Statements
Sales (ttm)$34.2M
EBITDA (ttm)-$7.36M
Income available to common (ttm)-$6.48M
Profitability
Profit Margin (ttm)-19.0%
Operating Margin (ttm)-22.0%
Fiscal Year
Fiscal Year EndsJune 30
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-17.24%
Return on Equity (ttm)-23.10%
Financial Strength
Current Ratio (mrq)2.72 
Debt/Equity (mrq)0 
Total Cash (mrq)$29.6M
Short Interest
As of 8-Aug-2001
Shares Short381.0K
Percent of Float3.5%
Shares Short
(Prior Month)
609.0K
Short Ratio3.73 
Daily Volume102.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Some event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.